GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Continuous on-line monitoring of secretion from rodent pituitary endocrine cells using fluorescent protein surrogate markers.
He. Z Z; Fernandez-Fuente. M M; Strom. M M; Cheung. L L; Robinson. I C IC; Le Tissier. P P
Key Findings
- GHRP-6 reliably stimulates growth hormone release in rodent pituitary tissue, confirming its secretagogue action.
- The fluorescent‑protein system provides high‑resolution, continuous monitoring of hormone secretion, revealing kinetic differences between stimuli.
- The technique can be adapted to other pituitary hormones (e.g., prolactin) and distinguishes effects of drugs like dopamine and oxytocin on secretion.
Practical Outcomes
- For biohackers, this study reinforces that GHRP-6 works as a GH‑releasing agent, but it doesn’t change dosing or safety guidance. The main value is scientific validation of its mechanism, not a new protocol. The method itself is a research tool and isn’t directly applicable to everyday self‑experimentation.
Summary
Scientists built a new lab tool that lets them watch hormone release in real time by using glowing proteins. They showed that the peptide GHRP-6 triggers growth hormone release in rat pituitary slices, and they could see how fast the response happens compared to other signals. The method also works for other hormones like prolactin, showing it can track different secretions.
Abstract
We have developed a system to use secreted fluorescent proteins (FPs) as surrogate markers for the continuous on-line monitoring of hormone release from perfused tissue slices. We have tested this system using GH-GFP transgenic rats with green fluorescent protein (GFP) targeted to the secretory vesicles (SVs) of pituitary growth hormone (GH) cells. Brief exposures of vibratome slices to GH secretagogues [GH-releasing hormone (GHRH), GH-releasing peptide-6 (GHRP-6)] or somatostatin caused changes in FP output that correlate with hormone secretion, subsequently measured in fractions of perfusate by radioimmunoassay. The temporal resolution of this method was capable of revealing differences in the kinetics of response to GHRH and GHRP-6 between wild-type and dwarf (dw/dw) rats harbouring the GH-GFP transgene. We further tested the utility of the system by generating transgenic mice with red FPs targeted to secretory vesicles (PRL-mRFP(sv)) and to the cytoplasm (PRL-DsRed(cyto)) of lactotrophs. Dopamine had no effect on the FP output from pituitary slices of PRL-DsRed(cyto) mice but inhibited output from those of PRL-mRFP(sv) animals, with a rebound increase of release after removal, which again correlated with hormone output measured in the perfusate by radioimmunoassay. The inhibition of monomeric RFP secretion by dopamine was dose-dependent, as was stimulation by low concentrations of oxytocin. The temporal resolution afforded by this method provides useful insight into the release kinetics from large populations of pituitary cells, and fills a temporo-spatial gap between single vesicle and single cell monitoring of exocytosis in milliseconds, and in vivo sampling studies of release into the bloodstream on a time scale of minutes.
Study Information
pubmed
2011
2011-03-01T00:00:00.000Z
10.1111/j.1365-2826.2010.02104.x
18
41